---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-055182"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T05:10:53.615945+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology nearing commercial launch of LYMPHIR for CTCL in H2 2025

## Summary
- Commercial-scale manufacturing completed; inventory sufficient for 12-18 months post-launch with 60-month shelf life.
- 70 institutional oncology centers already registered via the LYMPHIR website.
- LYMPHIR included in NCCN guidelines; assigned permanent J-code for reimbursement.
- Parent Citius Pharma's recent capital raise supports final launch preparations.
- Strategic partnership discussions underway with financial advisor to expand market reach.

## SEC filing metadata
- accession: 0001213900-25-055182
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025055182/0001213900-25-055182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025055182/ea0245933-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-055182
- JSON: https://secwatch.observer/filing/0001213900-25-055182.json
- Plain text: https://secwatch.observer/filing/0001213900-25-055182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.